Hasil Pencarian - Hamza Hashmi

  • Menampilkan 1 - 11 hasil dari 11
Perbaiki Hasil
  1. 1
    Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

    Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma oleh Kevin Miller, Hamza Hashmi, Sridevi Rajeeve

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient

    Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient oleh Hamza Hashmi, Drew Murray, Samer Al-Quran, William Tse

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge

    A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge oleh Hamza Hashmi, Drew Murray, John Greenwell, Marwan Shaikh, Soumit Basu, Maxwell Krem

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    “Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma

    “Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma oleh Kevin C. Graf, James A Davis, Alyssa Cendagorta, Katelynn Granger, Kelly J. Gaffney, Kimberly Green, Brian T Hess, Hamza Hashmi

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy oleh Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience

    Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium... oleh Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James Davis, Charlotte Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson Jr., Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, Melissa Alsina

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel oleh Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

    Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study oleh Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma, Romil Patel, Loretta Nastoupil, Sairah Ahmed, Reem Karmali

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

    Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment oleh Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy oleh Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium oleh Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castaneda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher J. Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B. Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: